Maxim Group Thinks Atossa Genetics’ Stock is Going to Recover

In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on Atossa Genetics (NASDAQ: ATOS), with a price target of $10. The company’s shares closed yesterday at $2.60, close to its 52-week low of $2.57.

McCarthy noted:

“Atossa completed an equity financing, raising $13.4M in capital. We estimate the company now has ~$16M in cash on the balance sheet or runway into late 2019, setting the stage for multiple catalysts to be reached, in our view.”

According to, McCarthy is a 4-star analyst with an average return of 10.1% and a 45.6% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, SELLAS Life Sciences Group Inc, and ContraVir Pharmaceuticals Inc.

Atossa Genetics has an analyst consensus of Moderate Buy, with a price target consensus of $10.

See today’s analyst top recommended stocks >>

The company has a one-year high of $19.08 and a one-year low of $2.57. Currently, Atossa Genetics has an average volume of 799.8K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Atossa Genetics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests.

Read More on ATOS:

From Our Partners